Advertisement

Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis

  • Lili Kokoti
  • Konstantina Drellia
  • Dimitrios Papadopoulos
  • Dimos D. MitsikostasEmail author
Original Communication
  • 96 Downloads

Abstract

High placebo and low nocebo phenomena mirror high positive expectations for a novel treatment, among other reasons. In a meta-analysis aimed to identify placebo and nocebo phenomena in the placebo-controlled randomized trials (RCTs) with the monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) all the placebo-treated patients were pooled and compared with the placebo-treated patients in RCTs with topiramate and onabotulinum toxin A (OBTA). In episodic migraine (EM), the proportion of placebo-treated patients who achieved the 50% responder rate (placebo) was 32.7% (95% CI 28.6%–37.0%) in anti-CGRP mAbs vs. 24.4% (95% CI 20.5%–28.5%) in topiramate trials. The proportion of dropouts due to adverse events in placebo-treated patients (nocebo) was 1.9% (95% CI 1.4%–2.6%) in anti-CGRP mAbs vs. 9.9% (95% CI 7.7%–12.3%) in topiramate RCTs. In chronic migraine (CM), the placebo 50% responder rate was 23.6% (95% CI 11.2%–38.8%) in anti-CGRP mAbs RCTs vs. 36.4% (95% CI 32.6%–39.3%) in RCTs with OBTA. The nocebo dropout in anti-CGRP mAbs and OBTA RCTs was 1.4% (95% CI 0.8%–2.1%) and 0.9 (95% CI 0.3%–1.7%), respectively. The stronger placebo and weaker nocebo phenomena in RCTs with anti-CGRP mAbs vs. those with topiramate in the prophylaxis of EM, may decisively determine anti-CGRP mAbs treatment success. No differences were detected between the anti-CGRP mAbs and OBTA in the treatment of CM.

Keywords

Episodic migraine Chronic migraine Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies Treatment Topiramate Onabotulinum toxin A 

Notes

Acknowledgements

The authors thank Mrs Evie Delicha, MSc, for her expert statistical advice.

Author contributions

All authors contributed to the study conception and design. Material preparation, literature search, data collection, and analysis were performed by KD and LK. The first draft of the manuscript was written by KD and LK and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Conceptualization: DDM; Methodology: DDM and DP; Formal analysis and investigation KD and LK; Writing—original draft preparation: KD and LK; Writing—review and editing: all authors; Funding acquisition: No founding; Supervision: DDM and DP.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflicts of interest

Dr. L. Kokoti reports no disclosures. Dr. K. Drellia reports no disclosures. Dr. D. Papadopoulos has received consulting, speaking fees and travel grants from Bayer, Genesis Pharma, Merck, Novartis, Roche, Sanofi-Aventis, Specifar and Teva. Prof. D.D. Mitsikostas has received consulting, speaking fees and travel grants from Allergan, Amgen, Bayer, Biogen, Cefaly, ElectroCore, Genesis Pharma, Eli Lilly, Merck-Serono, Merz, Mylan, Novartis, Roche, Sanofi-Genzyme, Specifar and Teva.

Ethical standards

No ethics approval or patient consent was obtained because all data used in this study were collected from previously published peer-reviewed articles.

Supplementary material

415_2019_9673_MOESM1_ESM.docx (21 kb)
Supplementary file1 (DOCX 21 kb)
415_2019_9673_MOESM2_ESM.docx (17 kb)
Supplementary file2 (DOCX 16 kb)
415_2019_9673_MOESM3_ESM.docx (16 kb)
Supplementary file3 (DOCX 16 kb)
415_2019_9673_MOESM4_ESM.docx (13 kb)
Supplementary file4 (DOCX 13 kb)

References

  1. 1.
    Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349PubMedCrossRefGoogle Scholar
  2. 2.
    Charles A (2013) Migraine: a brain state. Curr Opin Neurol 26:235–239PubMedCrossRefGoogle Scholar
  3. 3.
    Goadsby PJ, Sprenger T (2010) Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 9:285–298PubMedCrossRefGoogle Scholar
  4. 4.
    Silberstein SD (2005) Preventive treatment of migraine. Rev Neurol Dis 2:167–175PubMedGoogle Scholar
  5. 5.
    Gracia-Naya M, Santos-Lasaosa S, Ríos-Gómez C et al (2011) Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine. Rev Neurol 53:201–208PubMedGoogle Scholar
  6. 6.
    Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag care Pharm JMCP 20:22–33PubMedGoogle Scholar
  7. 7.
    Blumenfeld AM, Bloudek LM, Becker WJ et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53:644–655PubMedCrossRefGoogle Scholar
  8. 8.
    Edvinsson L, Ekman R, Jansen I et al (1987) Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 7:720–728PubMedCrossRefGoogle Scholar
  9. 9.
    Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23:193–196PubMedCrossRefGoogle Scholar
  10. 10.
    Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, BIBN 4096 BS Clinical Proof of Concept Study Group (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 350:1104–1110PubMedCrossRefGoogle Scholar
  11. 11.
    Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6:573–582PubMedCrossRefGoogle Scholar
  12. 12.
    Schuster NM, Rapoport AM (2017) Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache: a review. Clin Neuropharmacol 40:169–174PubMedCrossRefGoogle Scholar
  13. 13.
    Mitsikostas DD, Reuter U (2017) Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 30:272–280PubMedCrossRefGoogle Scholar
  14. 14.
    Mitsikostas DD, Rapoport AM (2015) New players in the preventive treatment of migraine. BMC Med 13:279PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Benedetti F, Lanotte M, Lopiano L et al (2007) When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 147:260–271PubMedCrossRefGoogle Scholar
  16. 16.
    Kennedy WP (1961) The nocebo reaction. Med. World 95:203–205PubMedGoogle Scholar
  17. 17.
    Barsky AJ, Saintfort R, Rogers MP et al (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287:622–627PubMedCrossRefGoogle Scholar
  18. 18.
    Colloca L, Miller FG (2011) The nocebo effect and its relevance for clinical practice. Psychosom Med 73:598–603PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Enck P, Benedetti F, Schedlowski M (2008) New insights into the placebo and nocebo responses. Neuron 59:195–206PubMedCrossRefGoogle Scholar
  20. 20.
    Mitsikostas DD (2012) Nocebo in Headaches: Implications for Clinical Practice and Trial Design. Curr Neurol Neurosci Rep 12:132–137PubMedCrossRefGoogle Scholar
  21. 21.
    Zaccara G, Giovannelli F, Giorgi FS et al (2016) Analysis of nocebo effects of antiepileptic drugs across different conditions. J Neurol 263:1274–1279PubMedCrossRefGoogle Scholar
  22. 22.
    Papadopoulos D, Mitsikostas DD (2010) Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler 6:816–828CrossRefGoogle Scholar
  23. 23.
    Stathis P, Smpiliris M, Konitsiotis S et al (2013) Nocebo as a potential confounding factor in clinical trials for Parkinson’s disease treatment: a meta-analysis. Eur J Neurol 20:527–533PubMedCrossRefGoogle Scholar
  24. 24.
    Mitsikostas DD, Mantonakis LI, Chalarakis NG (2011) Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 31:550–561PubMedCrossRefGoogle Scholar
  25. 25.
    Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, International Headache Society (2018) Clinical trials standing committee. Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38:815–832PubMedCrossRefGoogle Scholar
  26. 26.
    Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88:41–52PubMedCrossRefGoogle Scholar
  27. 27.
    Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963–974PubMedCrossRefGoogle Scholar
  28. 28.
    Lipton RB, Saper J, Ashina M et al (2018) A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine: results of the PROMISE-2 (prevention of migraine via intravenous eptinezumab safety and efficacy-2) trial. Neurology 90:e2193–e2194Google Scholar
  29. 29.
    Saper J, Lipton R, Kudrow D, Hirman J, Dodick D, Silberstein S, Chakhava GJS (2018) Primary results of PROMISE-1 (prevention of migraine via intravenous eptinezumab safety and efficacy–1) trial: a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraine. Neurology 90(15 Suppl):S20.001Google Scholar
  30. 30.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026–1037PubMedCrossRefGoogle Scholar
  32. 32.
    Goadsby PJ, Reuter U, Hallström Y et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123–2132PubMedCrossRefGoogle Scholar
  33. 33.
    Skljarevski V, Matharu M, Millen BA et al (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 38:1442–1454PubMedCrossRefGoogle Scholar
  34. 34.
    Stauffer VL, Dodick DW, Zhang Q et al (2018) Evaluation of galcanezumab for the prevention of episodic migraine. JAMA Neurol 75:1080PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine. JAMA 319:1999PubMedCrossRefGoogle Scholar
  36. 36.
    Detke HC, Goadsby PJ, Wang S et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211–e2221PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113–2122PubMedCrossRefGoogle Scholar
  38. 38.
    Silberstein SD, Neto W, Schmitt J et al (2004) Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61:490PubMedCrossRefGoogle Scholar
  39. 39.
    Brandes JL, Saper JR, Diamond M et al (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291:965PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Diener HC, Tfelt-Hansen P, Dahlöf C, Láinez MJ, Sandrini G, Wang SJ, Neto W, Vijapurkar U, Doyle A, JDM-003 SG (2004) Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J Neurol 251:943–950Google Scholar
  41. 41.
    Silberstein S, Hulihan J, Rezaulkarim M et al (2006) Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther 28:1002–1011PubMedCrossRefGoogle Scholar
  42. 42.
    Lipton RB, Silberstein S, Dodick D et al (2011) Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia 31:18–30PubMedCrossRefGoogle Scholar
  43. 43.
    Aurora S, Dodick D, Turkel C et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803PubMedCrossRefGoogle Scholar
  44. 44.
    Diener H, Dodick D, Aurora S et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814PubMedCrossRefGoogle Scholar
  45. 45.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC (2011) OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 51:1358–1373PubMedCrossRefGoogle Scholar
  46. 46.
    Gonçalves AL, Martini Ferreira A, Ribeiro RT et al (2016) Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 87:1127–1132PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Diener H-C, Schorn CF, Bingel U, Dodick DW (2008) The importance of placebo in headache esearch. Cephalalgia 8:1003–1011CrossRefGoogle Scholar
  48. 48.
    Amanzio M, Corazzini LL, Vase L, Benedetti F (2009) A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 146:261–269PubMedCrossRefGoogle Scholar
  49. 49.
    Mitsikostas DD, Chalarakis NG, Mantonakis LI et al (2012) Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 19:672–680PubMedCrossRefGoogle Scholar
  50. 50.
    Häuser W, Bartram C, Bartram-Wunn E et al (2012) Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy. Clin J Pain 28:437–451PubMedCrossRefGoogle Scholar
  51. 51.
    Papadopoulos D, Mitsikostas DD (2012) A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol 259:436–447PubMedCrossRefGoogle Scholar
  52. 52.
    Mitsikostas DD, Mantonakis L, Chalarakis N (2014) Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res. 215:82–86PubMedCrossRefGoogle Scholar
  53. 53.
    Meister R, Jansen A, Härter M, Nestoriuc Y, Kriston L (2017) Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder A meta-regression analysis. J Affect Disord. 215:288–298PubMedCrossRefGoogle Scholar
  54. 54.
    Dodd S, Schacht A, Kelin K, Dueñas H, Reed VA, Williams LJ, Quirk FH, Malhi GS, Berk M (2015) Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry. 76:702–711PubMedCrossRefGoogle Scholar
  55. 55.
    Zis P, Shafiq F, Mitsikostas D-D (2017) Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: systematic review and meta-analysis of placebo-controlled clinical trials. Seizure 45:95–99PubMedCrossRefGoogle Scholar
  56. 56.
    Zis P, Mitsikostas DD (2018) Nocebo responses in brain diseases: a systematic review of the current literature. Int Rev Neurobiol 139:443–462PubMedCrossRefGoogle Scholar
  57. 57.
    Colloca L (2017) Tell me the truth and I will not be harmed: informed consents and nocebo effects. Am J Bioeth 17:46–48PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Authors and Affiliations

  1. 1.1st Neurology Department, Aeginition Hospital, Medical SchoolNational and Kapodistrian University of AthensAthensGreece
  2. 2.Neurology ClinicAthens Medical Center-Paleo Phaliro ClinicAthensGreece

Personalised recommendations